title: Inhibition of protein glycation by procyanidin-B2 enriched fraction of cinnamon: delay of diabetic cataract in rats.
abstract: Accumulation of advanced glycation endproducts (AGE) from nonenzymatic glycation of proteins has been implicated in several diabetic complications including diabetic cataract. Previously, we have reported that extracts of dietary agents such as cinnamon have the potential to inhibit AGE formation. In this study, we have shown procyanidin-B2 as the active component of cinnamon that is involved in AGE inhibition using bioassay-guided fractionation of eye lens proteins under in vitro conditions. The data indicate that procyanidin-B2 enriched fraction scavenges dicarbonyls. Further, procyanidin-B2 fraction of cinnamon inhibited the formation of glycosylated hemoglobin in human blood under ex vivo conditions. We have also demonstrated the physiological significance of procyanidin-B2 fraction in terms of delay of diabetic cataract through inhibition of AGE in diabetic rats. These findings establish the antiglycating potential of procyanidin-B2 fraction of cinnamon which suggests a scope for controlling AGE-mediated diabetic complications by food sources that are rich in proanthocyanidins like procyanidin-B2.
authors.affiliation: Biochemistry Division, National Institute of Nutrition, Tarnaka, Hyderabad, India.
authors.forename: Puppala
authors.initials: P
authors.lastname: Muthenna
authors.forename: Ganugula
authors.initials: G
authors.lastname: Raghu
authors.forename: Chandrasekhar
authors.initials: C
authors.lastname: Akileshwari
authors.forename: Sukesh Narayana
authors.initials: SN
authors.lastname: Sinha
authors.forename: Palla
authors.initials: P
authors.lastname: Suryanarayana
authors.forename: Geereddy Bhanuprakash
authors.initials: GB
authors.lastname: Reddy
mesh_terms: D000818:Animals; D044946:Biflavonoids / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002386:Cataract / Q000517:prevention & control*; D002392:Catechin / Q000627:therapeutic use*; D002935:Cinnamomum zeylanicum / Q000737:chemistry*; D048909:Diabetes Complications / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental; D006442:Glycated Hemoglobin / Q000037:antagonists & inhibitors; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors; D006031:Glycosylation; D006801:Humans; D007908:Lens, Crystalline / Q000378:metabolism; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D044945:Proanthocyanidins / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D044946:Biflavonoids; D001786:Blood Glucose; D002392:Catechin; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D010936:Plant Extracts; D044945:Proanthocyanidins; C479580:procyanidin B2
keywords: advanced glycation end products; cinnamon; diabetic cataract; lens proteins; procyanidin-B2; protein glycation